Uncategorized
Emixustat from Acucela granted orphan drug designation for Stargardt disease
The FDA has granted orphan drug designation to a drug candidate for the treatment of Stargardt disease, Acucela announced in a press release.Acucela, which is a wholly owned subsidiary of Kubota Pharmaceutical Holdings, has been developing emixustat hydrochloride for the treatment of Stargardt disease, according to the release.